bio-STAT™ Biosensor Technology

Affimedix’s bio-STAT™ Biosensor Technology relies on the diagnostic gold standard of blood which eliminates the need for laboratory processing based on its Proprietary Biosensor design. Affimedix is an emerging leader in “Proprietary” Immuno-Sandwich Test technology for Small Molecule Biomarkers, and successfully markets its innovative Point-of-Care diagnostics.

Affimedix will continue to expand diagnostic biosensors for reliable at-home testing while relying on its homogeneous assay expertise. Affimedix is advancing its R&D efforts and taking steps toward enabling concierge medicine. Our biosensor will provide accurate, point-of-care results in under 60 seconds while requiring only a small volume of finger prick blood. Furthermore, our biosensor-based point-of-care tests can be marketed directly to the customers wishing to facilitate faster intervention and mitigation implementation. Our mission is to improve the quality of human healthcare by simplifying diagnostic decisions and expanding our biosensors for reliable at-home testing.